Emerging therapies, such as intranasal insulin-like growth factor 1 administration, epigenetic modulators, and vagus nerve stimulation, offer promising avenues for reducing CSD susceptibility and migraine frequency. This evidence concerns the gene IGF1 and migraine disorder.